Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | NAMPT | P43490 | 1/20 | 0.30 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.30 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12017377 | 0.84 | AR (0.41) | ARFFAR1ACHE | |
| SCHEMBL26389026 | 0.84 | AR (0.41) | ARFFAR1ACHE | |
| SCHEMBL19313559 | 0.80 | FADS1 (0.38) | ARROCK1 | |
| SCHEMBL30200569 | 0.79 | AR (0.40) | ARFFAR1 | |
| SCHEMBL5515968 | 0.77 | AR (0.38) | AR | |
| SCHEMBL1819606 | 0.76 | FFAR1 (0.55) | ARLRRK2FFAR1ROCK1NAMPT | |
| SCHEMBL15518451 | 0.76 | FFAR1 (0.37) | ARFFAR1 | |
| SCHEMBL14991007 | 0.76 | JAK2 (0.37) | AR | |
| SCHEMBL15885757 | 0.76 | GSK3B (0.33) | AR | |
| SCHEMBL26388990 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11958831-B2 | Pyrazole compounds, pharmaceutical compositions thereof and use thereof | ARTIVILA (SHENZHEN) INNOVATION CENTER, LTD. (CN) | 2024-04-16 | — | — | US | disclosed |
| EP-3845528-B1 | PYRAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND USE THEREOF AS IRAK4 INHIBITORS | ARTIVILA SHENZHEN INNOVATION CENTER LTD (CN) | 2023-10-11 | — | — | EP | disclosed |
| EP-3845528-B1 | PYRAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND USE THEREOF AS IRAK4 INHIBITORS | ARTIVILA SHENZHEN INNOVATION CENTER LTD (CN) | 2023-10-11 | — | — | EP | disclosed |
| WO-2023192901-A1 | QUINOLINE DERIVATIVES AS MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023179600-A1 | NOVEL SUBSTITUTED MACROHETEROCYCLIC COMPOUNDS AND USE THEREOF | 杭州德睿智药科技有限公司 | 2023-09-28 | — | — | WO | disclosed |
| US-11667649-B2 | Heteroaromatic macrocyclic ether chemotherapeutic agents | NUVALENT, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11667649-B2 | Heteroaromatic macrocyclic ether chemotherapeutic agents | NUVALENT, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-20230151016-A1 | PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230151016-A1 | PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230076627-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | NUVALENT, INC. | 2023-03-09 | — | — | US | disclosed |
| US-7705030-B2 | Amino-5-(5-membered)hetero-arylimidazolone compounds and the use thereof for β-secretase modulation | WYETH LLC (US) | 2010-04-27 | — | — | US | disclosed |
| US-20080306091-A1 | AMINO-5-(5-MEMBERED)HETERO-ARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR beta-SECRETASE MODULATION | WYETH (US) | 2008-12-11 | — | — | US | disclosed |
| US-20080306091-A1 | AMINO-5-(5-MEMBERED)HETERO-ARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR beta-SECRETASE MODULATION | WYETH (US) | 2008-12-11 | — | — | US | disclosed |
| US-20080306091-A1 | AMINO-5-(5-MEMBERED)HETERO-ARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR beta-SECRETASE MODULATION | WYETH (US) | 2008-12-11 | — | — | US | disclosed |
| US-7417047-B2 | Amino-5-(5-membered)hetero-arylimidazolone compounds and the use thereof for β-secretase modulation | WYETH (US) | 2008-08-26 | — | — | US | disclosed |
| US-7417047-B2 | Amino-5-(5-membered)hetero-arylimidazolone compounds and the use thereof for β-secretase modulation | WYETH (US) | 2008-08-26 | — | — | US | disclosed |
| US-7417047-B2 | Amino-5-(5-membered)hetero-arylimidazolone compounds and the use thereof for β-secretase modulation | WYETH (US) | 2008-08-26 | — | — | US | disclosed |
| US-20070004786-A1 | Amino-5-(5-membered)hetero-arylimidazolone compounds and the use thereof for beta-secretase modulation | WYETH (US) | 2007-01-04 | — | — | US | disclosed |
| US-20070004786-A1 | Amino-5-(5-membered)hetero-arylimidazolone compounds and the use thereof for beta-secretase modulation | WYETH (US) | 2007-01-04 | — | — | US | disclosed |
| US-20070004786-A1 | Amino-5-(5-membered)hetero-arylimidazolone compounds and the use thereof for beta-secretase modulation | WYETH (US) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11667649-B2 | Heteroaromatic macrocyclic ether chemotherapeutic agents | CYP2C8, ABCB1, PAICS | AR 135/4885LRRK2 4217/4885FFAR1 4290/4885 |
| US-20230076627-A1 | HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS | CYP2C8, ABCB1, PAICS | AR 135/4885LRRK2 4217/4885FFAR1 4290/4885 |
| US-11958831-B2 | Pyrazole compounds, pharmaceutical compositions thereof and use thereof | IRAK3, IRAK1, IRAK2 | AR 3191/4885LRRK2 509/4885FFAR1 2325/4885 |
| US-20070004786-A1 | Amino-5-(5-membered)hetero-arylimidazolone compounds and the use thereof for beta-secretase modulation | BACE1, BACE2, APP | AR 3419/4885LRRK2 54/4885FFAR1 3887/4885 |
| US-20080306091-A1 | AMINO-5-(5-MEMBERED)HETERO-ARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR beta-SECRETASE MODULATION | BACE1, BACE2, APP | AR 3419/4885LRRK2 54/4885FFAR1 3887/4885 |
| US-20230151016-A1 | PYRROLIDINE-PYRAZOLES AS PYRUVATE KINASE ACTIVATORS | PDK1, PDK2, PKM | AR 3857/4885LRRK2 684/4885FFAR1 2863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.